ISRG
INTUITIVE SURGICAL INCEvidence as of 2026-09-03Overview · INTUITIVE SURGICAL INC
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery int…
Management team
- Dr. Brian Miller Ph.D. · Executive VP & Chief Digital OfficerFind on LinkedIn
- Dr. Myriam J. Curet McAdams F.A.C.S., M.D. · Executive VP & Chief Medical OfficerFind on LinkedIn
- Mr. Julian Nikolchev · Senior Vice President of Corporate Development & VenturesFind on LinkedIn
- Mr. Henry L. Charlton · Senior VP & Chief Commercial and Marketing OfficerFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.2 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
Evidence balance is Mixed ( -0.2 of a possible +2; was -0.2 before debate) · confidence high. Revenue by fiscal quarter has risen from 2,253,400,000 in Q1 2025 (fiscal quarter ended 2025-04-15) to 2,892,300,000 in Q2 2026 (fiscal quarter ended 2026-07-16). Gross profit increased in the same span from 1,457,700,000 to 1,960,400,000, implying gross margin expansion from about 64.7% to about 67.8%.
Net income shows higher recent profitability, moving from 698,400,000 in Q1 2025 to 818,100,000 in Q2 2026, with diluted EPS rising from 1.92 to 2.29. Reported shares outstanding declined by roughly 11.3 million from 364,600,000 as of 2025-03-31 to 353,278,038 as of 2026-07-16, and cash paid for repurchase of common stock of 1,123,200,000 is reported for the quarter ended 2026-03-31 (fiscal Q1 2026). Cash and cash equivalents on the shown balance-sheet dates moved from 3,368,000,000 (as of 2025-12-31) to 2,760,400,000 (as of 2026-06-30), a decline of about 607.6 million.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue by fiscal quarter has risen over the sample: 2,253,400,000 (Q1 2025, 2025-01-01 to 2025-03-31), 2,440,000,000 (Q2 2025, 2025-04-01 to 2025-06-30), 2,505,100,000 (Q3 2025, 2025-07-01 to 2025-09-30), 2,770,800,000 (Q1 2026, 2026-01-01 to 2026-03-31), and 2,892,300,000 (Q2 2026, 2026-04-01 to 2026-06-30).
XBRL companyfacts · 0001035267-25-000109Gross profit for the same quarters has increased from 1,457,700,000 (Q1 2025) to 1,617,900,000 (Q2 2025), 1,662,400,000 (Q3 2025), 1,830,500,000 (Q1 2026) and 1,960,400,000 (Q2 2026), implying gross margin expansion from about 64.7% (1,457,700,000 / 2,253,400,000) in Q1 2025 to about 67.8% (1,960,400,000 / 2,892,300,000) in Q2 2026.
XBRL companyfacts · 0001035267-26-000032Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
A Form 4 filing with the 4 filed 19 August 2026 was submitted on 2026-08-19.
4 filed 2026-08-19A Form 4 filing with the 4 filed 21 August 2026 was submitted on 2026-08-21.
4 filed 2026-08-21Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum measures are negative: 3-month momentum is -8.7%, 6-month momentum is -25.8%, and 12-1 momentum is -23.8% (percentiles: 6-month momentum ranks in the 5th percentile of 547; 12-1 momentum ranks in the 13th percentile of 547).
Moneyta signal set · 2026-09-02weakened in debatePrice is below moving averages: price vs 50-day SMA is -2.7% and price vs 200-day SMA is -20.1% (golden_cross = false).
Moneyta signal set · 2026-09-02Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, ISRG is a holding in the IVV ETF with a weight of 0.22% of that fund.
ETF constituents · market dataA Form 4 filing for ISRG with the 4 filed 19 August 2026 was filed on 2026-08-19 (parse_status: skipped; primary_doc_url: null).
Form 4 × 2 (90d window not enforced here)Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets note the company's share price has fallen significantly this year, describing it as the firm's "worst stretch in years" and saying the stock has dropped more than 30% year-to-date.
News · finance.yahoo.com · 2026-09-02Several pieces highlight a renewed or heavier R&D push by the company, with coverage referencing investments in AI, robotics and new procedures.
News · simplywall.st · 2026-09-02Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Total insider activity in the past 180 days shows $150k sold, $0 bought, net change of -385 shares.
Form 4 · Brosius Mark (EVP & Chief Mfg and Supply Cha) · $29k sold · 2026-08-21Mark Brosius (EVP & Chief Mfg and Supply Cha) sold 77 shares for $29k on 2026-08-21 under a stated 10b5-1 plan.
Form 4 · Brosius Mark (EVP & Chief Mfg and Supply Cha) · $29k sold · 2026-08-21Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model shows an implied free cash flow (FCF) growth rate of 50.6% (0.506) that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-FCF (price / trailing twelve-month FCF) is 90.12 based on a price of 371.88 and trailing twelve-month FCF of 1,474,400,000.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The balance of company-filed fundamentals shows rising top-line and gross-profit trends across the sampled quarters, expanding gross margins, higher quarterly net income and diluted EPS, and an observable reduction in shares outstanding coincident with over $1.1B of share repurchases in a quarter — together these items point to improving reported operating profitability and active capital return. These items are drawn from SEC filings and period financials, which are primary-source evidence and therefore strong for assessing recent historical performance. Counterarguments based on weak momentum, drawdown, elevated volatility, and rich trailing multiples rely on market-price and model outputs that reflect past price action and trailing flows; those signals are also strong for describing market sentiment but do not negate the filing-backed improvement in operating results. Insider sales cited in Form 4 entries are small in aggregate and repeatedly reported as 10b5-1 plan activity, which reduces the evidentiary weight of those transactions as a signal of company fundamentals. News items pointing to renewed R&D and company-specific strategic commentary further support a constructive read when paired with the filing evidence, while market-derived negatives and valuation-model outputs are strong evidence of market sentiment and price-based valuation pressure that bear against a favorable market-view but do not contradict the reported operational improvements.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.33
35 surviving claims rest on 16 distinct sources; the heaviest analyst carries 20% of them, and 99% of what the desk raised survived the debate.
The read rests on a moderate breadth of sources but a relatively small set overall; multiple claims draw from the same filings and computed signal sets, so individual source errors could affect several claims. One analyst contributing 20% of surviving claims and a 99% survival rate through debate suggests low internal pushback — the signals may be well-aligned but also exposed to analyst-dependence or confirmation bias, so treat the net view as informative but not definitive.
Peer context · computed, not argued
12-1 momentum ranks 4th of 4 in Medical Instruments & Supplies (as of 2026-09-02).
6-month relative strength ranks 4th of 4 in Medical Instruments & Supplies (as of 2026-09-02).
90-day volatility ranks 1st of 4 in Medical Instruments & Supplies (as of 2026-09-02).
dividend yield ranks 3rd of 4 in Medical Instruments & Supplies (as of 2026-09-02).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
13 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.9 to the score
2 documents
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−1.2 to the score
2 holdings records
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.3 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
2 filings· 1 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot−1.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on ISRG Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.